Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership

Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.